T2 Biosystems is a biotechnology company focused on transforming the way infectious diseases are diagnosed
The company's innovative molecular diagnostic platform enables rapid and accurate detection of a wide range of pathogens, including bacteria and fungi, using blood samples. By providing timely results, T2 Biosystems aims to enhance clinical decision-making, improve patient outcomes, and reduce the overall burden of infectious diseases. Their commitment to developing advanced diagnostic tools positions them as a leader in the field of point-of-care testing and infectious disease management.
NEW YORK, NY / ACCESSWIRE / August 13, 2024 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day August Micro-Cap Conference taking place Wednesday and Thursday, August 14-15, 2024. The presentation schedule is subject to change. Please visit www.sidoti.com/events for the most updated version and webinar links.
Shares of Riot Platforms, Inc. (NASDAQRIOT) rose sharply in today's pre-market trading amid a rise in Bitcoin. Bitcoin (CRYPTO: BTC) prices gained around 1.5% over the past 24 hours to $66,012 this morning.
Shares of Big Lots, Inc. (NYSEBIG) fell sharply during Monday’s session after the company reported preliminary fourth-quarter results. Also, Loop Capital downgraded the stock from Hold to Sell and lowered its price target from $6 to $1.
T2 Biosystems said that it has received FDA clearance to add the capability to detect another bacterial species, Acinetobacter baumannii, to the panel. "We are thrilled to receive the FDA 510(k) clearance for the expanded T2Bacteria Panel, to include the detection of A. baumannii, as we believe it will lead to increased adoption of our proprietary direct-from-blood platform," stated John Sperzel, CEO of T2 Biosystems.
